Circulating perivascular progenitors: A target of PDGFR inhibition

International Journal of Cancer

Volumn 129, Issue 6, 2011, Pages 1344-1350

  Mancuso, Patrizia ^a   Martin Padura, Ines ^a   Calleri, Angelica ^a   Marighetti, Paola ^a   Quarna, Jessica ^a   Rabascio, Cristina ^a   Braidotti, Paola ^b   Bertolini, Francesco ^a  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

angiogenesis; anti PDGFR; antiangiogenic therapy; circulating perivascular progenitors; PDGFR

Indexed keywords

CD31 ANTIGEN; CD45 ANTIGEN; CYCLOPHOSPHAMIDE; DNA; MESSENGER RNA; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; PLATELET DERIVED GROWTH FACTOR RECEPTOR; SUNITINIB;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL DIFFERENTIATION; CELL FUNCTION; CELL KINETICS; CELL SELECTION; CELL STRUCTURE; CELL VIABILITY; CONTROLLED STUDY; DRUG MEGADOSE; DRUG TARGETING; ENDOTHELIAL PROGENITOR CELL; FLOW CYTOMETRY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; LIVER CELL CARCINOMA; NONHUMAN; PERICYTE; PERIVASCULAR PROGENITOR CELL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SINGLE DRUG DOSE; STEM CELL; TRANSMISSION ELECTRON MICROSCOPY;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTIGENS, CD31; BONE MARROW CELLS; CELL COUNT; CELL DIFFERENTIATION; CELL SURVIVAL; HUMANS; INDOLES; MICE; NEOPLASMS; PERICYTES; PYRROLES; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR BETA; STEM CELLS;

EID: 79960898784     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.25816     Document Type: Article

References (32)

1. Gerhardt H, Betsholtz C,. Endothelial-pericyte interactions in angiogenesis. Cell Tissue Res 2003; 314: 15-23. (Pubitemid 37409909)
2. Hirschi KK, Rohovsky SA, D'Amore PA,. PDGF, TGF-β, and heterotypic cell-cell interactions mediate endothelial cell-induced recruitment of 10T1/2 cells and their differentiation to a smooth muscle fate. J Cell Biol 1998; 141: 805-14. (Pubitemid 28217923)
3. Hellstrom M, Kalen M, Lindahl P, Abramsson A, Betsholtz C,. Role of PDGF-B and PDGFR-β in recruitment of vascular smooth muscle cells and pericytes during embryonic blood vessel formation in the mouse. Development 1999; 126: 3047-55. (Pubitemid 29378170)
4. Betsholtz C, Karlsson L, Lindahl P,. Developmental roles of platelet-derived growth factors. Bioessays 2001; 23: 494-507. (Pubitemid 32575610)
5. Leveen P, Pekny M, Gebre-Medhin S, Swolin B, Larson E, Bestholtz C,. Mice deficient for PDGF B show renal, cardiovascular, and hematological abnormalities. Genes Dev 1994; 8: 1875-87. (Pubitemid 24273888)
6. Lindahl P, Johansson B, Leveen P, Betsholtz C,. Pericyte loss and microaneurysm formation in PDGF-B-deficient mice. Science 1997; 126: 3047-55.
7. Benjamin L, Hemo I, Keshet E,. A plasticity window for blood vessel remodelling is defined by pericyte coverage of the preformed endothelial network and is regulated by PDGF-B and VEGF. Development 1998; 125: 1591-8. (Pubitemid 28256727)
8. Morikawa S, Baluk P, Kaidoh T, Haskell A, Jain RK, McDonald D,. Abnormalities in pericytes on blood vessels and endothelial sprouts in tumors. Am J Pathol 2002; 160: 985-1000. (Pubitemid 34224587)
9. + perivascular progenitor cells in tumours regulate pericyte differentiation and vascular survival. Nat cell Biol 2005; 7: 870-9. (Pubitemid 41486287)
10. Cabebe E, Wakelee H,. Sunitinib: a newly approved small-molecule inhibitor of angiogenesis (review). Drugs Today 2006; 42: 387-98. (Pubitemid 44090113)
11. Agliano A, Martin-Padura I, Marighetti P, Rabascio C, Prineri G, Shultz LD, Bertolini F,. Human acute leukemia cells injected in NOD/LtSz-scid/IL- 2Rgamma null mice generate a faster and more efficient disease compared to other NOD/scid-related strains. Int J Cancer 2008; 123: 2222-7.
12. Tang TC, Man S, Lee CR, Xu P, Kerbel RS,. Impact of metronomic UFT/cyclophosphamide chemotherapy and antiangiogenic drug assessed in a new preclinical model of locally advanced orthotopic hepatocellular carcinoma. Neoplasia 2010; 12: 264-74.
13. Mancuso P, Antoniotti P, Quarna J, Calleri A, rabascio C, Tacchetti C, Braidotti P, Wu HK, Zurita AJ, Saronni L, Cheng JB, Shalinsky DR, et al. Validation of a standardized method for enumerating circulating endothelial cells and progenitors: flow cytometry, molecular and ultrastructural analyses. Clin Cancer Res 2009; 15: 267-73.
14. van der Pol MA, Broxterman HJ, Westra G, Ossenkoppele GJ, Schuurhuis GJ,. Novel multiparameter flow cytometry assay using Syto16 for the simultaneous detection of early apoptosis and apoptosis-corrected P-glycoprotein function in clinical samples. Cytometry B Clin Cytom 2003; 55: 14-21. (Pubitemid 38295404)
15. Confalonieri S, Salcini AE, Puri C, Tacchetti C, Di Fiore PP,. Tyrosine phosphorylation of Eps15 is required for ligand-regulated, but not constitutive, endocytosis. J Cell Biol 2000; 150: 905-12.
16. Rabascio C, Muratori E, Mancuso P, Calleri A, Raia V, Foutz T, Cinieri S, Veronesi G, Pruneri G, Lampertico P, Iavarone M, Martinelli G, et al. Assessing tumor angiogenesis: increased circulating VE-cadherin RNA in patients with cancer indicates viability of circulating endothelial cells. Cancer Res 2004; 64: 4373-7. (Pubitemid 38802446)
17. Niclou SP, Danzeisen C, Eikesdal HP, Wiig H, Brons NH, Poli AM, Svendsen A, Torsvik N, Enger PO, Terzis JA, Bjerkvig R,. A novel eGFP-expressing immunodeficient mouse model to study tumor-host interactions. FASEB J. 2008; 9: 3120-8.
18. Kerbel RS,. Tumor angiogenesis. New Engl J Med 2008; 358: 2039-49. (Pubitemid 351656458)
19. Mancuso P, Colleoni M, Calleri A, Orlando L, Maisonneuve P, Pruneri G, Agliano A, Goldhirsch A, Shaked Y, Kerbel RS, Bertolini F,. Circulating endothelial cell kinetics and viability predict survival in breast cancer patients receiving metronomic chemotherapy. Blood 2006; 108: 452-9. (Pubitemid 44061341)
20. Dellapasqua S, Bertolini F, Bagnardi V, Campagnoli E, Scarano E, Torrisi R, Shaked Y, Mancuso P, Goldhirsch A, Rocca A, Pietri E, Colleoni M,. Metronomic cyclophosphamide and capecitabine combined with bevacizumab in advanced breast cancer. J Clin Oncol 2008; 26: 4899-905.
21. Calleri A, Bono A, Bagnardi V, Quarna J, Mancuso P, Dellapasqua S, Campagnoli E, Shaked Y, Goldhirsch A, Colleoni M, Bertolini F,. Predictive potential of angiogenic growth factors and circulating endothelial cells in breast cancer patients receiving metronomic chemotherapy plus bevacizumab. Clin Cancer Res 2009; 15: 7652-7.
22. Beaudry P, Force J, Naumov GN, Wang A, Baker CH, Rayan A, Soker S, Johnson BE, Folkman J, Heymach JV,. Differential effects of vascular endothelial growth factor receptor-2 inhibitor ZD6474 on circulating endothelial progenitors and mature circulating endothelial cells: implications for use as a surrogate marker of antiangiogenic activity. Clin Cancer Res 2005; 11: 3514-22. (Pubitemid 40627906)
23. Norden-Zfoni A, Desai J, Manola J, Beaudry P, Force J, Marki R, Folkman J, Bello C, Baum C, De Primo SE, Shalinsky DR, Demetri GD, et al. Blood-based biomarkers of SU11248 activity and clinical outcome in patients with metastatic imatinib-resistant gastrointestinal stromal tumor. Clin Cancer Res 2007; 13: 2643-50. (Pubitemid 46788031)
24. Batchelor TT, Sorensen AG, di Tomaso E, Zhang WT, Duda DT, Cohen KS, Kozak KR, Cahill DP, Chen PJ, Zhu M, Ancukiewicz M, Mrugala MM, et al. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 2007; 11: 83-95. (Pubitemid 46075199)
25. Roodhart JM, Langenberg HM, Vermaat JS, Loikema MP, Baars A, Giles RH, Vitteveen EO, Voest EE,. Late release of circulating endothelial cells and endothelial progenitor cells after chemotherapy predicts response and survival in cancer patients. Neoplasia 2010; 12: 87-94.
26. Stijbos HM, Gratama JW, Schmitz PI, Rao C, Onstenk W, Doyle GV, Miller MC, de Wit R, Terstappen LW, Sleijfer S,. Circulating endothelial cells, circulating tumour cells, tissue factor, endothelin-1 and overall survival in prostate cancer patients treated with docetaxel. Eur J Oncol 2010; 46: 2027-35.
27. Ronzoni M, Manzoni M, Mariucci S, Loupakis F, Brugnatelli S, Bencardino K, Rovati B, Tinelli C, Falcone A, Villa E, Danova M,. Circulating endothelial cells and endothelial progenitors as predictive markers of clinical response to bevacizumab-based first-line treatment in advanced colorectal cancer patients. Ann Oncol 2010; 21: 2382-9.
28. Ning YM, Gulley JL, Arlen PM, Woo S, Steinber SM, Wright JJ, Parnes HL, Trepel JB, Lee MJ, Kim YS, Sun H, Madan RA, et al. Phase II trail of bevacizumab, thalidomide, docetaxel and prednisone in patients with metastatic, castration-resistant prostate cancer. J Clin Oncol 2010; 28: 2070-6.
29. Bidard FC, Mathiot C, Degeorges A, Etienne-Grimaldi MC, Delva R, Pivot X, Veyret C, Bergougnoux L, De Cremoux P, Milano G, Pierga YJ,. Clinical value of circulating endothelial cells and circulating tumor cells in metastatic breast cancer patients treated first line with bevacizumab and chemotherapy. Ann Oncol 2010; 21: 1765-71.
30. Bertolini F, Paul S, Mancuso P, Monestiroli S, Gobbi A, Shaked Y, Kerbel RS,. Maximum tolerable dose and low-dose metronomic chemotherapy have opposite effects on the mobilization and viability of circulating endothelial progenitor cells. Cancer Res 2003; 63: 4342-6. (Pubitemid 36951001)
31. Bertolini F, Martinelli G, Goldhirsch A,. High-dose chemotherapy for breast cancer: the relevance of mosaic tumor blood vessels. Lancet Oncol 2001; 2: 596.
32. Kachel DL, Martin WJ, II,. Cyclophosphamide-induced lung toxicity: mechanism of endothelial cell injury. J Pharmacol Exp Ther 1994; 268: 42-6. (Pubitemid 24039066)